Il-Jin Kim, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Il-Jin Kim, PhD

Assistant Professor, Department of Surgery, University of California at San Francisco

kimij@cc.ucsf.edu

Phone: (415) 502-6791

UCSF Profiles

Cancer Center Membership

Associate Member » Non-aligned

Research Summary

Dr. Il-Jin Kim is a Principal Investigator and Director of Applied Genomics in the UCSF Thoracic Oncology Program. His work focuses on the identification of novel diagnostic markers and therapeutic targets in various types of human cancers. Dr. Kim investigates human cancers using state-of-the-art technologies including next-generation sequencing (NGS) and system genetics, Dr. Kim has developed several innovative microarrays (RET, beta-catenin, K-ras, and BRAF) and pioneered new methods of high-throughput mutation screening for which he holds numerous patents. He is also an inventor of the World-fast targeted NGS technologies (DNA/RNA extraction, new targeted NGS library prep, NGS data analysis program, and data interpretation tool).

Dr. Il-Jin Kim has identified novel potential diagnostic markers and/or therapeutic targets for human cancers using Integrative Systems Genetics system that he developed with his colleagues, such as PEBP4 (novel type II pneumocyte gene/marker for lung – Nature Commun, 2013), VRK1 (novel cancer-specific mitosis marker and a potential therapeutic target– Nature Commun, 2013), GREM1 (potential lung cancer oncogene and diagnostic marker (lung adenocarcinoma) – Plos One, 2012), and SETDB1 (one of the frequently mutated genes and a potential therapeutic target in malignant mesotheliomas –Oncotarget, 2016).

His research and paper for the 'Prediction of response to preoperative chemoradiotherapy in colorectal cancer patients' was named the best publication of 2007 by the journal "Dis Colon Rectum", the award given at the 2008 ASCRS (American Society of Colon and Rectal Surgeons) Annual Meeting. He has also three times received awards for development of innovative genetic and diagnostic assays by AACR (American Association for Cancer Research).

Dr. Il-Jin Kim served as a group leader of the Korean Hereditary Tumor Registry from 2001-2006, an organization of which he has been a member since 1999. As group leader, he led a project that screened approximately 1,000 patients from 400 hereditary cancer families, looking at 12 inherited cancer syndromes. Dr. Kim graduated the College of Veterinary Medicine , Seoul National University with a B.S. and D.V.M. (Magna Cum Laude) , and an M.S. and Ph.D. in Tumor Biology from the College of Medicine at Seoul National University. In 2010, Dr. Kim joined the UCSF faculty in the Department of Surgery.

Journal Editor.

2012-present: ISRN Biotechnology,

2013-present: Journal of Surgery

Education

College of Veterinary Medicine, Seoul National University, Korea,    B.S., D.V.M.,    1999,    Veterinary Medicine
College of Medicine, Seoul National University, Korea,    M.S.,    2001,    Tumor Biology
College of Medicine, Seoul National University, Korea,    Ph.D.,    2003,    Tumor Biology
College of Medicine, Seoul National University, Korea,    Post-doc,    2003-2006,    Cancer Genetics
Cancer Research Institute, University of California San Francisco,       Post-doc,    2007-2008,    Cancer Genetics
 


Professional Experience

  • 3/2008-6/2010
    Assistant Research Geneticist, Cancer Research Institute, University of California at San Francisco, USA
  • 7/2010-present
    Assistant Professor (Full-time), Department of Surgery, University of California at San Francisco, USA
  • 2011-present
    Director, Applied Genomics, Thoracic Oncology Program, University of California at San Francisco, USA

Honors & Awards

  • 1999
    Graduation with Honors (Cum Laude), Seoul National University, Korea

  • 2002
    Best Research Award, Korea Cancer Research Foundation, Korea

  • 2003
    AACR ITO-EN Scholar-In-Training Award, American Association for Cancer Research, USA

  • 2003
    Best Research Award, Korea Cancer Research Foundation, Korea

  • 2003-2004
    BK21 (Brain Korea 21) Postdoctoral Fellowship, Korea

  • 2004
    Best Research Award, Korea Cancer Research Foundation, Korea

  • 2004
    Outstanding Science and Technology Publication Award, Korean Federation of Science and Technology Societies, Korea

  • 2004
    National Cancer Center Travel Award to AACR annual meeting, Korea

  • 2005
    AACR ITO-EN Scholar-In-Training Award, American Association for Cancer Research, USA

  • 2005
    Best Research Award, National Cancer Center, Korea

  • 2005
    GlaxoSmithKline (GSK) Award from Korean Cancer Association, Korea

  • 2006
    AACR ITO-EN Scholar-In-Training Award, American Association for Cancer Research, USA

  • 2008
    Impact Paper of the Year Award, The American Society of Colon and Rectal Surgeons, USA

  • 2012
    Uniting Against Lung Cancer Research Grant Award, Uniting Against Lung Cancer, USA

Selected Publications

  1. Dang J, Mendez P, Lee S, Kim JW, Yoon JH, Kim TW, Sailey CJ, Jablons DM, Kim IJ. Development of a robust DNA quality and quantity assessment qPCR assay for targeted next-generation sequencing library preparation. Int J Oncol. 2016 Aug 11.
    View on PubMed
  2. Mendez P, Dang J, Kim JW, Lee S, Yoon JH, Kim T, Sailey CJ, Jablons DM, Kim IJ. Comprehensive evaluation and validation of targeted next-generation sequencing performance in two clinical laboratories. Int J Oncol. 2016 Jul; 49(1):235-42.
    View on PubMed
  3. Kang HC, Kim HK, Lee S, Mendez P, Kim JW, Woodard G, Yoon JH, Jen KY, Fang LT, Jones K, Jablons DM, Kim IJ. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. Oncotarget. 2016 Feb 16; 7(7):8321-31.
    View on PubMed
  4. Agostini M, Janssen KP, Kim IJ, D'Angelo E, Pizzini S, Zangrando A, Zanon C, Pastrello C, Maretto I, Digito M, Bedin C, Jurisica I, Rizzolio F, Giordano A, Bortoluzzi S, Nitti D, Pucciarelli S. An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancer. Oncotarget. 2015 Oct 20; 6(32):32561-74.
    View on PubMed
  5. Letteboer TG, Benzinou M, Merrick CB, Quigley DA, Zhau K, Kim IJ, To MD, Jablons DM, van Amstel JK, Westermann CJ, Giraud S, Dupuis-Girod S, Lesca G, Berg JH, Balmain A, Akhurst RJ. Genetic variation in the functional ENG allele inherited from the non-affected parent associates with presence of pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia 1 (HHT1) and may influence expression of PTPN14. Front Genet. 2015; 6:67.
    View on PubMed
  6. Zhang S, Yang YL, Wang Y, You B, Dai Y, Chan G, Hsieh D, Kim IJ, Fang LT, Au A, Stoppler HJ, Xu Z, Jablons DM, You L. CK2a, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells. J Exp Clin Cancer Res. 2014; 33:93.
    View on PubMed
  7. Fang LT, Lee S, Choi H, Kim HK, Jew G, Kang HC, Chen L, Jablons D, Kim IJ. Comprehensive genomic analyses of a metastatic colon cancer to the lung by whole exome sequencing and gene expression analysis. Int J Oncol. 2014 Jan; 44(1):211-21.
    View on PubMed
  8. Kim HK, Jablons DM, Kim IJ.. Multistep Progression from Atypical Adenomatous Hyperplasia to Lung Adenocarcinoma: Clinico-Pathologic, Epigenetic and Genetic Aspects. J Surgery. 2013; 1(1):10.
    View on PubMed
  9. Bosco-Clément G, Zhang F, Chen Z, Zhou HM, Li H, Mikami I, Hirata T, Yagui-Beltran A, Lui N, Do HT, Cheng T, Tseng HH, Choi H, Fang LT, Kim IJ, Yue D, Wang C, Zheng Q, Fujii N, Mann M, Jablons DM, He B. Targeting Gli transcription activation by small molecule suppresses tumor growth. Oncogene. 2014 Apr 17; 33(16):2087-97.
    View on PubMed
  10. Kang HC, Quigley DA, Kim IJ, Wakabayashi Y, Ferguson-Smith MA, D'Alessandro M, Birgitte Lane E, Akhurst RJ, Goudie DR, Balmain A. Multiple self-healing squamous epithelioma (MSSE): rare variants in an adjacent region of chromosome 9q22.3 to known TGFBR1 mutations suggest a digenic or multilocus etiology. J Invest Dermatol. 2013 Jul; 133(7):1907-10.
    View on PubMed
  11. Kim IJ, Quigley D, To MD, Pham P, Lin K, Jo B, Jen KY, Raz D, Kim J, Mao JH, Jablons D, Balmain A. Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas. Nat Commun. 2013; 4:1701.
    View on PubMed
  12. Mulvihill MS, Kwon YW, Lee S, Fang LT, Choi H, Ray R, Kang HC, Mao JH, Jablons D, Kim IJ. Gremlin is overexpressed in lung adenocarcinoma and increases cell growth and proliferation in normal lung cells. PLoS One. 2012; 7(8):e42264.
    View on PubMed
  13. Kim JW, Lee S, Lui N, Choi H, Mulvihill M, Fang LT, Kang HC, Kwon YW, Jablons D, Kim IJ. A somatic TSHR mutation in a patient with lung adenocarcinoma with bronchioloalveolar carcinoma, coronary artery disease and severe chronic obstructive pulmonary disease. Oncol Rep. 2012 Oct; 28(4):1225-30.
    View on PubMed
  14. Zhang S, Wang Y, Mao JH, Hsieh D, Kim IJ, Hu LM, Xu Z, Long H, Jablons DM, You L. Inhibition of CK2a down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells. PLoS One. 2012; 7(6):e38996.
    View on PubMed
  15. Kwon YW, Kim IJ, Wu D, Lu J, Stock WA, Liu Y, Huang Y, Kang HC, DelRosario R, Jen KY, Perez-Losada J, Wei G, Balmain A, Mao JH. Pten regulates Aurora-A and cooperates with Fbxw7 in modulating radiation-induced tumor development. Mol Cancer Res. 2012 Jun; 10(6):834-44.
    View on PubMed
  16. Choi H, Kratz J, Pham P, Lee S, Ray R, Kwon YW, Mao JH, Kang HC, Jablons D, Kim IJ. Development of a rapid and practical mutation screening assay for human lung adenocarcinoma. Int J Oncol. 2012 Jun; 40(6):1900-6.
    View on PubMed
  17. Mao JH, Wu D, Kim IJ, Kang HC, Wei G, Climent J, Kumar A, Pelorosso FG, DelRosario R, Huang EJ, Balmain A. Hipk2 cooperates with p53 to suppress ?-ray radiation-induced mouse thymic lymphoma. Oncogene. 2012 Mar 1; 31(9):1176-80.
    View on PubMed
  18. Quigley DA, To MD, Kim IJ, Lin KK, Albertson DG, Sjolund J, Pérez-Losada J, Balmain A. Network analysis of skin tumor progression identifies a rewired genetic architecture affecting inflammation and tumor susceptibility. Genome Biol. 2011; 12(1):R5.
    View on PubMed
  19. Climent J, Perez-Losada J, Quigley DA, Kim IJ, Delrosario R, Jen KY, Bosch A, Lluch A, Mao JH, Balmain A. Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer. J Clin Oncol. 2010 Aug 10; 28(23):3770-8.
    View on PubMed
  20. Hung MS, Lin YC, Mao JH, Kim IJ, Xu Z, Yang CT, Jablons DM, You L. Functional polymorphism of the CK2alpha intronless gene plays oncogenic roles in lung cancer. PLoS One. 2010; 5(7):e11418.
    View on PubMed

Go to UCSF Profiles, powered by CTSI